SAN ANTONIO, TX--(Marketwire - March 23, 2009) -
| Highlighted Links |
The MacReport.Net |
Vanguard's team performed a full analysis on the public and private oncology market and found sufficient margins on its product line that will allow it to have a viable business in Peru. Vanguard Pharmaceutical expects to have a further competitive advantage as it has the largest generic oncology line in Peru. Its manufacturer has high quality drugs that adhere to the World Health Organization (WHO) guidelines, Good Manufacturing Practices (GMP) and is ISO 9001 certified unlike most of its public competitors. In addition the manufacturer has the ability to quickly extend its product range due to its non infringing patent technology for new APIs that are developed in-house through committed R&D.
Vanguard is ready to embrace the Peruvian oncology market and believes it has a solid footing to succeed in the market.
About Vanguard Pharmaceutical
In an era of ageing populations, rising health care costs, and increasing cancer cases Vanguard's mission is to decrease health care expenditures by selling affordable oncology and generic drugs and by investing in research to find a noninvasive cure for cancer.
Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure. Vanguard is currently targeting Latin America for its oncology and generic pharmaceutical sales as it is believed to have a substantially unmet demand for advanced generics and entry into the market can be done with relative ease. Latin America is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009.
A noninvasive cure for cancer will revolutionize our health care system by highly reducing hospital stays as patients will not have to go through life threatening chemotherapy and radiation which could save health care systems billions of dollars. Vanguard's team is researching several new technologies such as telomerase inhibitor therapy, nanoparticle therapies, and low power radio frequency radiation. Vanguard plans to partner with established clinical centers and universities to further develop these technologies then license them out. It has also discussed performing trials in Latin American oncology centers.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Statements in this
release that are forward-looking statements are based on current
expectations and assumptions that are subject to known and unknown risks,
uncertainties, or other factors which may cause actual results,
performance, or achievements of the company to be materially different from
any future results, performance, or achievements expressed or implied by
such forward-looking statements. Actual results could differ materially
because of factors such as the effect of general economic and market
conditions, entry into markets with vigorous competition, market acceptance
of new products and services, continued acceptance of existing products and
services, technological shifts, and delays in product development and
related product release schedules, any of which may cause revenues and
income to fall short of anticipated levels. All information in this release
is as of the date of this release. The company undertakes no duty to update
any forward-looking statement to conform the statement to actual results or
changes in the company's expectations.
